Research programme: apoptosis inducers - Adamed

Drug Profile

Research programme: apoptosis inducers - Adamed

Alternative Names: ONCO-3CLA

Latest Information Update: 08 Jan 2014

Price : $50

At a glance

  • Originator Adamed
  • Class
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Solid tumours

Most Recent Events

  • 08 Jan 2014 Research programme: apoptosis inducers - Adamed is available for licensing as of 08 Jan 2014. http://www.adamed.com.pl
  • 06 Jan 2014 Early research in Solid tumours in Poland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top